Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation

Emile Salloum, Anand P. Jillella, Rajani Nadkarni, Stuart Seropian, Grace L. Hu, Elizabeth D'Andrea, Daniel Zelterman, Dennis L. Cooper

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.

Original languageEnglish (US)
Pages (from-to)1506-1512
Number of pages7
JournalCancer
Volume82
Issue number8
DOIs
StatePublished - Apr 15 1998

Fingerprint

Cell Transplantation
Blood Cells
Stem Cells
Drug Therapy
Lung
Respiratory Function Tests
Transplantation
Vital Capacity
Gated Blood-Pool Imaging
Lung Volume Measurements
Total Lung Capacity
Carmustine
Melphalan
Cytarabine
Bleomycin
Forced Expiratory Volume
Etoposide
Carbon Monoxide
Hodgkin Disease
Stroke Volume

Keywords

  • BEAM
  • Cardiac toxicity
  • High dose chemotherapy
  • Peripheral blood progenitor cell transplantation
  • Pulmonary toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. / Salloum, Emile; Jillella, Anand P.; Nadkarni, Rajani; Seropian, Stuart; Hu, Grace L.; D'Andrea, Elizabeth; Zelterman, Daniel; Cooper, Dennis L.

In: Cancer, Vol. 82, No. 8, 15.04.1998, p. 1506-1512.

Research output: Contribution to journalArticle

Salloum, Emile ; Jillella, Anand P. ; Nadkarni, Rajani ; Seropian, Stuart ; Hu, Grace L. ; D'Andrea, Elizabeth ; Zelterman, Daniel ; Cooper, Dennis L. / Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. In: Cancer. 1998 ; Vol. 82, No. 8. pp. 1506-1512.
@article{b87a18b6339e4643873460dcb9f79b7d,
title = "Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation",
abstract = "BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70{\%} of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.",
keywords = "BEAM, Cardiac toxicity, High dose chemotherapy, Peripheral blood progenitor cell transplantation, Pulmonary toxicity",
author = "Emile Salloum and Jillella, {Anand P.} and Rajani Nadkarni and Stuart Seropian and Hu, {Grace L.} and Elizabeth D'Andrea and Daniel Zelterman and Cooper, {Dennis L.}",
year = "1998",
month = "4",
day = "15",
doi = "10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8",
language = "English (US)",
volume = "82",
pages = "1506--1512",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation

AU - Salloum, Emile

AU - Jillella, Anand P.

AU - Nadkarni, Rajani

AU - Seropian, Stuart

AU - Hu, Grace L.

AU - D'Andrea, Elizabeth

AU - Zelterman, Daniel

AU - Cooper, Dennis L.

PY - 1998/4/15

Y1 - 1998/4/15

N2 - BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.

AB - BACKGROUND. Limited information is available regarding the cardiac and pulmonary effects of high dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell (PBPC) transplantation. METHODS. The authors evaluated cardiac and pulmonary function after BEAM (BCNU 300 mg/m2, etoposide 400 mg/m2/day x 3 days, cytosine arabinoside 200 mg/m2/day x 4 days, and melphalan 140 mg/m2), HDCT, and PBPC transplantation in 26 patients with non-Hodgkin's lymphoma or Hodgkin's disease. Therapy prior to BEAM included doxorubicin (25 patients), bleomycin (6 patients), and mediastinal irradiation (4 patients). All patients had pulmonary function tests (PFTs) and equilibrium radionuclide angiography before and at a median of 57 weeks after transplantation. RESULTS. Prior to high dose therapy, 8 patients had abnormal PFTs, including 6 with a diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted value. At the time of reevaluation after HDCT, all patients included in the study were in complete remission, and none had received additional therapy after transplantation. At a median of 77 weeks after transplantation, none of the patients had cardiac or pulmonary symptoms. Moreover, there were no significant changes in total lung capacity, forced vital capacity, forced expiratory volume in 1 second/forced vital capacity, DLCO, or left ventricular ejection fraction values when compared with baseline studies. CONCLUSIONS. The authors concluded that HDCT with BEAM and PBPC transplantation did not result in significant cardiac or pulmonary toxicity, even in patients with borderline pretransplantation PFT values. Further studies of patients undergoing HDCT and PBPC transplantation are needed.

KW - BEAM

KW - Cardiac toxicity

KW - High dose chemotherapy

KW - Peripheral blood progenitor cell transplantation

KW - Pulmonary toxicity

UR - http://www.scopus.com/inward/record.url?scp=0032523083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032523083&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0142(19980415)82:8<1506::AID-CNCR12>3.0.CO;2-8

M3 - Article

C2 - 9554528

AN - SCOPUS:0032523083

VL - 82

SP - 1506

EP - 1512

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -